AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 37062658
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of immuno-oncology drug and a tyrosine kinase inhibitor (TKI)
Trial: 37062834
Drug: Metformin (open-label)
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin (open-label)
Trial: 37062953
Drug: Triplet combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triplet combination of cabozantinib, nivolumab, and ipilimumab
Trial: 37062953
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of pembrolizumab plus lenvatinib plus belzutifan
Trial: 37062953
Drug: Doublet combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doublet combination therapy with immune checkpoint inhibitors or immune checkpoint and tyrosine kinase inhibitor
Trial: 37063238
Drug: Ad26.COV2.S vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad26.COV2.S vaccine (Janssen/Johnson & Johnson), single dose
Trial: 37065899
Drug: CBD (Epidiolex®)
RxNorm normalized name: Epidiolex
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: CBD (Epidiolex®) 600 mg
Trial: 37066198
Drug: Behavioral treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral treatments for RA
Trial: 37066249
Drug: Acalabrutinib 100
RxNorm normalized name: acalabrutinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acalabrutinib 100 mg twice daily for four doses
Trial: 37066828
Drug: VYC-15L treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VYC-15L treatment group
Trial: 37067525
Drug: PARP inhibitors
RxNorm normalized name: Poly (ADP-ribose) polymerase (PARP) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PARP inhibitors (PARPis)
Trial: 37067525
Drug: Subsequent chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subsequent chemotherapy after PARPis
Trial: 39652156
Drug: Mosunetuzumab monotherapy
RxNorm normalized name: Mosunetuzumab
DrugBank: Mosunetuzumab (DB15434)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mosunetuzumab monotherapy
Trial: 37068273
Drug: Oral fluvoxamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fluvoxamine (100 mg twice daily for 10 days) plus inhaled budesonide (800 mcg twice daily for 10 days)
Trial: 37068889
Drug: Inhaled volatile
RxNorm normalized name: Peppermint volatile oil
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled volatile anaesthesia (INVA)
Trial: 37068892
Drug: Repeated cervical
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated cervical ripening with prostaglandins (slow-release vaginal dinoprostone; oral misoprostol 25 µg; dinoprostone vaginal gel 2 mg)
Trial: 37069359
Drug: Motixafortide and
RxNorm normalized name: Motixafortide
DrugBank: Motixafortide (DB14939)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motixafortide and G-CSF
Trial: 37069364
Drug: SEL-037 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SEL-037 0.2 mg/kg + SEL-110 0.1-0.15 mg/kg
Trial: 37069364
Drug: SEL-037 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SEL-037 0.2 mg/kg alone
Trial: 37069364
Drug: SEL-037 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SEL-037 0.2 mg/kg + SEL-110 0.15 mg/kg
Trial: 37069364
Drug: SEL-110 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SEL-110 at doses up to 0.1 mg/kg
Trial: 37069490
Drug: Standard Behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Behavioral Treatment (ST)
Trial: 37730530
Drug: Intradialytic exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradialytic exercise (60 min during the second hour of thrice weekly dialysis for 6 months)
Trial: 37069970
Drug: Ertugliflozin 5
RxNorm normalized name: ertugliflozin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ertugliflozin 5 mg or 15 mg (doses pooled for analyses)
Trial: 37070436
Drug: Empagliflozin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin (10 mg once daily for 12 weeks)
Trial: 37070473
Drug: Warfarin (vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (vitamin K antagonist)
Trial: 37070653
Drug: Aromatase inhibitor
RxNorm normalized name: Aromatase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitor + CDK4/6 inhibitor
Trial: 37070673
Drug: Living in
RxNorm normalized name: Typhoid Vaccine Live
DrugBank: Typhoid Vaccine Live (DB11050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Living in extreme poverty (defined as below 120% of federal poverty thresholds) during ALL maintenance therapy.
Trial: 37070673
Drug: Not living
RxNorm normalized name: Typhoid Vaccine Live
DrugBank: Typhoid Vaccine Live (DB11050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not living in extreme poverty (above 120% of federal poverty thresholds) during ALL maintenance therapy.
Trial: 37071166
Drug: Experimental group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental group (0.7 mL/kg iohexol 350 mgI/mL)
Trial: 37071166
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (1.4 mL/kg iohexol 350 mgI/mL)
Trial: 37071469
Drug: L-ficolin, hyaluronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-ficolin, hyaluronic acid (HA), and stimulation 2 (ST2) measured on day 3 after HCT
Trial: 37071469
Drug: Low L-ficolin
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low L-ficolin levels
Trial: 37071469
Drug: L-ficolin levels
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-ficolin levels
Trial: 38722221
Drug: Avelumab first-line
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab first-line maintenance therapy
Trial: 37072105
Drug: AZD4831 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD4831 5 mg
Trial: 37072361
Drug: Risperidone (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (oral run-in)
Trial: 37072603
Drug: Photobiomodulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation therapy (PBMT) with gallium-aluminum-arsenide (GaAlAs) diode laser (810 nm, continuous-wave mode, 1000 mW, 0.28 cm)
Trial: 37072607
Drug: Repository Corticotropin
RxNorm normalized name: Repository Corticotropin Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repository Corticotropin Injection (RCI, 80 U, subcutaneous, twice weekly for 24 weeks)
Trial: 37072607
Drug: Repository Corticotropin
RxNorm normalized name: Repository Corticotropin Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repository Corticotropin Injection (RCI)
Trial: 37072812
Drug: 15-week specialized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15-week specialized low-intensity rehabilitation program, including exercise and respiratory therapy and mental gait training
Trial: 37073421
Drug: Aspirin (prophylactic,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (prophylactic, dosage not specified)
Trial: 37073442
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine and bupivacaine (100 μg morphine and 15 mg bupivacaine)
Trial: 37073794
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (discontinued anti-fibrotic therapy > 5 medication half-lives)
Trial: 37073926
Drug: AneuFix elastomer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AneuFix elastomer injection into the endoleak cavity and lumbar arteries
Trial: 37074202
Drug: mRNA-1283 vaccine
RxNorm normalized name: ChulaCov19 mRNA vaccine
DrugBank: ChulaCov19 mRNA vaccine (DB16445)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1283 vaccine
Trial: 37074571
Drug: Surufatinib 300
RxNorm normalized name: Surufatinib
DrugBank: Surufatinib (DB15106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surufatinib 300 mg QD
Trial: 37074571
Drug: Surufatinib 300
RxNorm normalized name: Surufatinib
DrugBank: Surufatinib (DB15106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surufatinib 300 mg QD (pNET cohort)
Trial: 37074571
Drug: Surufatinib 300
RxNorm normalized name: Surufatinib
DrugBank: Surufatinib (DB15106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surufatinib 300 mg QD (epNET cohort)
Trial: 37074571
Drug: Surufatinib 300
RxNorm normalized name: Surufatinib
DrugBank: Surufatinib (DB15106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surufatinib 300 mg QD (both cohorts)
Trial: 37074698
Drug: Brief Interpersonal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief Interpersonal Therapy (IPT)
Trial: 37074775
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (SOC) for PrEP choice (oral or CAB-LA)
Trial: 37075129
Drug: 20 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 μg of H1ssF once
Trial: 37075254
Drug: 177 Lu-DOTA-EB-TATE
RxNorm normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 177 Lu-DOTA-EB-TATE without amino acid infusion
Trial: 37075254
Drug: 177 Lu-DOTA-EB-TATE
RxNorm normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 177 Lu-DOTA-EB-TATE with amino acid infusion
Trial: 37075255
Drug: Weekly dose-dense
RxNorm normalized name: selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly dose-dense chemotherapy
Trial: 37075255
Drug: Standard three-weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard three-weekly carboplatin-paclitaxel regimens
Trial: 37075617
Drug: Mobocertinib 160
RxNorm normalized name: Mobocertinib
DrugBank: Mobocertinib (DB16390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mobocertinib 160 mg QD
Trial: 37075617
Drug: Real-world treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real-world treatments (EGFR TKI 20%, immuno-oncology therapy 40%, chemotherapy 40%)
Trial: 37075781
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg plus gemcitabine and cisplatin
Trial: 37075965
Drug: 8-week self-administered
RxNorm normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8-week self-administered dyadic intervention (ReStoreD) consisting of activities completed individually and as a couple.
Trial: 37076132
Drug: Risk-based follow-up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risk-based follow-up strategies for G-(MA)NEC
Trial: 37076159
Drug: Flexible care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flexible care with subcutaneous atezolizumab (1875 mg; Day 1 of each 21-day cycle) administered in the hospital, followed by 13 cycles at home by a healthcare professional
Trial: 37076252
Drug: Bupivacaine implant
RxNorm normalized name: bupivacaine Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine implant (300 mg, three 100 mg implants)
Trial: 37076252
Drug: Placebo (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (three collagen implants)
Trial: 37076424
Drug: Beta-lactam therapeutic
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-lactam therapeutic drug monitoring (BL TDM)
Trial: 37076476
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (metformin with or without insulin)
Trial: 37077305
Drug: Ophthalmic DMPC-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmic DMPC-based nanoemulsion (Nanodrop®)
Trial: 37077916
Drug: Golidocitinib (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Golidocitinib (5 - 150 mg single dose; 25 - 100 mg once daily for 14 days)
Trial: 37077916
Drug: Golidocitinib (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Golidocitinib (50 mg) under fed conditions
Trial: 37077916
Drug: Golidocitinib (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Golidocitinib (25 - 150 mg single dose)
Trial: 37077916
Drug: Golidocitinib (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Golidocitinib (50 mg)
Trial: 37077927
Drug: Biofilm disrupting
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biofilm disrupting acne cream 2x
Trial: 37077927
Drug: Biofilm disrupting
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biofilm disrupting acne cream 1x
Trial: 37077927
Drug: Biofilm disrupting
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biofilm disrupting acne cream without salicylic acid
Trial: 37078004
Drug: Simultaneous integrated
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simultaneous integrated boost (SIB) with concurrent chemotherapy
Trial: 37078188
Drug: Active Control
RxNorm normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Control (CTRL) therapy
Trial: 37078412
Drug: Entospletinib 400
RxNorm normalized name: Entospletinib
DrugBank: Entospletinib (DB12121)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entospletinib 400 mg twice daily with decitabine 20 mg/m²
Trial: 37078706
Drug: Orelabrutinib 150
RxNorm normalized name: Orelabrutinib
DrugBank: Orelabrutinib (DB16272)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orelabrutinib 150 mg once daily
Trial: 37078706
Drug: Orelabrutinib 100
RxNorm normalized name: acalabrutinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orelabrutinib 100 mg twice daily
Trial: 37078706
Drug: Orelabrutinib (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orelabrutinib (both doses)
Trial: 37078771
Drug: Piperacillin-tazobactam (3.375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin-tazobactam (3.375 or 4 g intravenously)
Trial: 37078771
Drug: Cefoxitin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin (2 g intravenously; standard care)
Trial: 37078969
Drug: Goal-focused Emotion-regulation
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Goal-focused Emotion-regulation Therapy (GET)
Trial: 37079305
Drug: Daily-life fall
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily-life fall rates
Trial: 37079305
Drug: Other daily-life
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other daily-life fall-related metrics
Trial: 37079324
Drug: Stereotactic radiosurgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic radiosurgery (SRS) with a single dose of 16 or 18 Gy to involved vertebral levels
Trial: 37079363
Drug: Mobile Acceptance
RxNorm normalized name: Chamaemelum nobile extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile Acceptance and Commitment Therapy (ACT) intervention
Trial: 37079518
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with small LLD (indicating better prognosis and better anti-VEGF treatment response).
Trial: 37079851
Drug: Content control
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Content control with nonimmersive tablet computer (Tablet Blu)
Trial: 37079894
Drug: Rifabutin triple
RxNorm normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifabutin triple therapy (14-day esomeprazole 20 mg, amoxicillin 1.0 g, rifabutin 150 mg twice a day)
Trial: 37079894
Drug: Bismuth quadruple
RxNorm normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth quadruple therapy (esomeprazole 20 mg, bismuth 220 mg twice a day, metronidazole 400 mg, tetracycline 500 mg 4 times a day)
Trial: 37080223
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (carboplatin and paclitaxel) after standard cisplatin-based chemoradiotherapy
Trial: 37080223
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (carboplatin and paclitaxel)
Trial: 37080462
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg PP + CC
Trial: 37080462
Drug: PP (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PP (doses ≤150 mg)
Trial: 37080829
Drug: Half-dose MVC-COV1901
RxNorm normalized name: MVC-COV1901
DrugBank: MVC-COV1901 (DB15854)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-dose MVC-COV1901
Trial: 37080829
Drug: Full-dose MVC-COV1901
RxNorm normalized name: MVC-COV1901
DrugBank: MVC-COV1901 (DB15854)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose MVC-COV1901
Trial: 37080829
Drug: Half-dose mRNA-1273
RxNorm normalized name: MRNA-1273 SARS-COV-2
DrugBank: Moderna COVID-19 Vaccine (DB15654)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-dose mRNA-1273
Trial: 37080942
Drug: E7130 administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E7130 administered intravenously at 480 μg/m (Q3W)
Trial: 37080942
Drug: E7130 administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E7130 administered intravenously at 480 μg/m (Q2W)
Trial: 37081029
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil and evening primrose oil (EPO) supplementation (2 gel capsules of fish oil and 3 gel capsules of EPO for 12 weeks)
Trial: 37081029
Drug: Mineral oil
RxNorm normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mineral oil (placebo, 5 gel capsules of 1g for 12 weeks)
Trial: 37081046
Drug: Tocilizumab/infliximab with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab/infliximab with standard treatment
Trial: 37081046
Drug: Tocilizumab with
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab with standard treatment
Trial: 37081406
Drug: Intensive Neurophysiological
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive Neurophysiological Rehabilitation System (INRS) treatment
Trial: 37081406
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (waiting list for 4 weeks, then INRS treatment)
Trial: 37081406
Drug: INRS treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INRS treatment
Trial: 37081426
Drug: Intravenous Lutetium-177
RxNorm normalized name: Lutetium-177
DrugBank: Lutetium Lu-177 (DB13982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Lutetium-177 PSMA Radioligand Therapy (RLT) followed by one fraction of HDR brachytherapy
Trial: 37081426
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose rate (HDR) brachytherapy in two fractions (standard of care salvage treatment)
Trial: 37081534
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Suubi intervention components
Trial: 37081617
Drug: Guideline-recommended treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-recommended treatment (ACE inhibitors, ARBs)
Trial: 37081722
Drug: Pyrotinib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrotinib (400 mg)
Trial: 37081722
Drug: Pyrotinib plus
RxNorm normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrotinib plus docetaxel (60 mg)
Trial: 37082098
Drug: Cemiplimab 350
RxNorm normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cemiplimab 350 mg every 3 weeks (Q3W)
Trial: 37082098
Drug: Chemotherapy (platinum-doublet)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (platinum-doublet)
Trial: 38272571
Drug: Intravenous nerinetide
RxNorm normalized name: Nerinetide
DrugBank: Nerinetide (DB12595)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nerinetide
Trial: 37083300
Drug: Non-BMX treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-BMX treatments
Trial: 37083360
Drug: Novel kit
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel kit formulation targeting fibroblast activation protein (FAP)
Trial: 37083461
Drug: Mixed nuts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed nuts (42g daily)
Trial: 37083461
Drug: Potato chips
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potato chips (46g daily)
Trial: 37083664
Drug: Esketamine (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esketamine (0.25 mg/kg intravenous injection)